A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib and tislelizumab in unresectable hepatocellular carcinoma

被引：0
|
作者：
Zhong, Jian-Hong [1 ]
Chen, Zu-Shun [1 ]
Qi, Lu-Nan [1 ]
Zhang, Zhi-Ming [1 ]
Xiang, Bang-De [1 ]
Ma, Liang [1 ]
机构：
[1] Guangxi Med Univ Canc Hosp, Nanning, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16219
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
    Liu, Bao-Jiang
    Gao, Song
    Zhu, Xu
    Guo, Jian-Hai
    Zhang, Xin
    Chen, Hui
    Wang, Xiao-Dong
    Yang, Ren-Jie
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (06) : 663 - 676
  • [32] Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
    Bao-Jiang Liu
    Song Gao
    Xu Zhu
    Jian-Hai Guo
    Xin Zhang
    Hui Chen
    Xiao-Dong Wang
    Ren-Jie Yang
    World Journal of Gastrointestinal Oncology, 2020, (06) : 663 - 676
  • [33] Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
    Sun, Bo
    Zhang, Lijie
    Sun, Tao
    Ren, Yanqiao
    Cao, Yanyan
    Zhang, Weihua
    Zhu, Licheng
    Guo, Yusheng
    Gui, Yuxi
    Liu, Fengyong
    Chen, Lei
    Xiong, Fu
    Zheng, Chuansheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Efficacy and Safety of Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven: A Multicentre, Retrospective Propensity Score Matching Analysis
    Zhong, Sheng
    Zhang, Fengtao
    Zhang, Haiming
    Hu, Honglei
    Zeng, Quan
    Li, Yangyang
    Wei, Qiming
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2025, 12 : 445 - 458
  • [35] Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma
    Xu, Yongkang
    Fu, Shumin
    Mao, Ye
    Huang, Shenglan
    Li, Dan
    Wu, Jianbing
    FRONTIERS IN MEDICINE, 2022, 9
  • [36] The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study
    Cai, Yingxiao
    Wen, Wu
    Xia, Yangshuo
    Wan, Renhua
    CURRENT ONCOLOGY, 2025, 32 (02)
  • [37] Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
    Xin, Yujing
    Cao, Fei
    Yang, Hongcai
    Zhang, Xinyuan
    Chen, Yi
    Cao, Xiaojing
    Zhou, Xiang
    Li, Xiao
    Zhou, Jinxue
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [38] Efficacy and safety of hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma
    Yamashita, Tatsuya
    Terashima, Takeshi
    Arai, Kuniaki
    Sunagozaka, Hajime
    Yamashita, Taro
    Mizukoshi, Eishiro
    Sakai, Akito
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY, 2012, 56 : 471A - 471A
  • [39] A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
    Teng, Ying
    Ding, Xiaoyan
    Li, Wendong
    Sun, Wei
    Chen, Jinglong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [40] The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: A phase II clinical trial
    Liang, Guo
    Gu, Shanzhi
    Guo, Yabing
    Li, Hailiang
    Liu, Jingfeng
    Liu, Jibing
    Huang, Ming
    Zou, Yinghua
    Huang, Luke
    Zhang, Yangyang
    Liu, Ting
    Liu, Wei
    Wang, Zhongmin
    Li, Baiyong
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 478 - 478
12345